COMP <GO>
ADRX vs AGIO // FORWARD P/E MULTIPLE
ADARx Pharmaceuticals Inc. (NASDAQ) VS. Agios Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ADRX 0
— AGIO 2
■ METRIC PARITY
LAST: $15.76 (-7.29%) • MKT CAP: $1.82B
forward-pe
—
LAST: $29.95 (-1.96%) • MKT CAP: $1.82B
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADRX VS. AGIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADRX | AGIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -33.80% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -16.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 48.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 11.84 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 4/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.5 | 42.5 | -9.01 | AGIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.82B | $1.82B | -$8.3M | AGIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADRX REV | AGIO REV | ADRX GROSS % | AGIO GROSS % | ADRX FCF | AGIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $54.0M | — | 88.3% | — | -$377.3M |
| FY 2024 | — | $36.5M | — | 88.6% | — | -$391.5M |
| FY 2023 | — | $26.8M | — | — | — | -$296.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADRX // BETA —
AGIO // BETA —